Advertisement
News
Advertisement

GTC Biotherapeutics makes a profit by regaining ATryn drug rights

Wed, 10/27/2010 - 10:37am
Mass High Tech: The Journal of New England Technology

GTC Biotherapeutics Inc. reported a profit of $3.5 million for the third quarter of 2010, compared with a loss of $5.1 million, or 48 cents per share, for the third quarter of 2009.

The Framingham-based developer of therapeutic proteins produced through transgenic animal technology said the improved financial performance was due to the recognition of non-cash revenue associated with regaining rights to ATryn, a recombinant human antithrombin from its former partner. GTC officials said ATryn, which is approved both in the U.S. and Europe, is the first therapeutic product produced in transgenic animals to be approved anywhere in the world.

SOURCE

Topics

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading